Please ensure Javascript is enabled for purposes of website accessibility
TUCC | The Urology Center of Colorado Logo

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer; results of a phase 3, randomized, placebo-controlled trial

TUCC physician Lawrence Karsh, M.D., was a lead principal investigator in this Phase III, double-blind, randomised, placebo-controlled study of men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis published in The Lancet in January 2012.

Read Article

We’re here to help.

For appointments at any TUCC location, request an appointment online.